A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting now

Conditions studied: Prostatic Neoplasms, Castration-Resistant

In brief

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Key facts

Study ID

NCT07677254

Run by

Novartis Pharmaceuticals

People needed

17111

Starts

2026-06-30

Expected to finish

2026-11-30

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older, up to 115. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
• Male sex at index, where index is the date of initial mCRPC diagnosis.
• Age 18 years at index.

You may not qualify if…

• None

Where it is running

• Novartis — East Hanover, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.